1 – 10 of 17
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Recombinant FVIII replacement products for haemophilia A : An updated valuation by indirect comparison measuring area under the curve
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
The formal care costs of dementia : a longitudinal study using Swedish register data
2024) In European Journal of Health Economics(
- Contribution to journal › Article
- 2023
-
Mark
Burden of established cardiovascular disease in people with type 2 diabetes and matched controls : Hospital-based care, days absent from work, costs and mortality
(
- Contribution to journal › Article
-
Mark
Model-based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease
(
- Contribution to journal › Article
-
Mark
Area under the curve : Comparing the value of factor VIII replacement therapies in haemophilia A
(
- Contribution to journal › Article
- 2022
-
Mark
Healthcare costs of dementia diseases before, during and after diagnosis : Longitudinal analysis of 17 years of Swedish register data
(
- Contribution to journal › Article
-
Mark
Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting
(
- Contribution to journal › Article
-
Mark
Effect of self-managed lifestyle treatment on glycemic control in patients with type 2 diabetes
(
- Contribution to journal › Article
- 2020
-
Mark
Costs of diabetes complications : hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden
(
- Contribution to journal › Article
-
Mark
Days absent from work as a result of complications associated with type 2 diabetes : Evidence from 20 years of linked national registry data in Sweden
(
- Contribution to journal › Article